2014 Lipoprotein Metabolism Gordon Research Conference and Gordon Research Semina

描述(由申请人提供)： 我们请求部分支持2014年脂蛋白代谢戈登研究会议(GRC)和戈登研究研讨会(GRS)，会议将于2014年6月16-20日在NH的沃特维尔山谷度假村举行。联席主席小罗伯特·法雷塞博士和Joachim Herz与该领域的前任主席、2016年副主席和该领域的领导者协商后，为GRC计划了9次口头会议：第1次会议脂肪酶会议2次肝脏和肠脂代谢会议3高密度脂蛋白与胆固醇反向运输4次脂蛋白受体和血管壁会议5中枢神经系统和脂质代谢会议6次细胞内脂肪代谢会议7关于脂质和脂蛋白代谢的简短演讲和主旨演讲第8次会议脂和脂蛋白代谢的遗传学第9次会议脂质和心血管疾病的治疗在GRC之前将举行脂蛋白代谢GRS会议，这是一个供研究生和博士后展示和讨论前沿研究的国际论坛。我们的会议满足了NHLBI使命的各个方面。首先，我们聚集了脂蛋白代谢领域的国际领先者，脂蛋白代谢是一种生理过程，占全球心血管风险负担的30%以上。其次，已经确定了与性别有关的遗传、生物学、生化和脂蛋白的临床表现问题，因此我们的会议满足了NHLBI在女性中解决这些问题的责任。此外，三名讨论负责人是女性，两名领导人来自欧洲，一名来自加拿大。国际公认的人类遗传学家海伦·霍布斯博士将作主旨演讲。第三，我们的会议经过了仔细的协调，包括了与血脂异常和心血管疾病的病因、预防、诊断和治疗有关的各种研究。第四，NHLBI传统上支持我们的会议，我们很荣幸邀请NHLBI管理部门的精选成员作为与会者。第五，我们赞同NHLBI对预防的优先考虑；事实上，我们在过去的会议上首次报告了目前广泛应用于常规临床的心血管疾病一级和二级预防的关键方面(例如他汀类药物)。第六，联合主席把个人在培训初期和职业发展初期的参与放在最高优先位置。

DESCRIPTION (provided by applicant): We request partial support for the 2014 Lipoprotein Metabolism Gordon Research Conference (GRC) and Gordon Research Seminar (GRS) to be held at Waterville Valley Resort, NH on June 16-20, 2014. The Co- Chairs, Drs. Robert Farese, Jr. and Joachim Herz, in consultation with past chairs, the 2016 vice chairs, and leaders in the field, have planned nine oral sessions for the GRC: Session 1 Lipases Session 2 Hepatic & Intestinal Lipid Metabolism Session 3 HDL & Reverse Cholesterol Transport Session 4 Lipoprotein Receptors and Vascular Wall Session 5 CNS & Lipids Session 6 Intracellular Lipid Metabolism Session 7 SHORT TALKS FROM ABSTRACTS AND Keynote Talk on Lipid and Lipoprotein Metabolism Session 8 Genetics of Lipid and Lipoprotein Metabolism Session 9 Therapeutics of Lipid and Cardiovascular Disease The GRC will be preceded by the Lipoprotein Metabolism GRS, an international forum for the presentation and discussion of frontier research by graduate students and postdoctoral fellows. Our conference satisfies all aspects of the NHLBI Mission. First, we bring together international leaders in lipoprotein metabolism, a physiological process that accounts for more than 30% of global cardiovascular risk burden. Second, gender-related issues of genetics, biology, biochemistry, and clinical manifestations of lipoproteins have been identified, so our conference satisfies the NHLBI responsibility for addressing these issues in women. Also, three Discussion Leaders are women, and two leaders are from Europe originally and one from Canada. Dr. Helen Hobbs, an internationally recognized human geneticist, will be a keynote speaker. Third, our conference has been carefully coordinated to include a diversity of research that is related to the causes, prevention, diagnosis and treatment of dyslipidemias and cardiovascular disease. Fourth, the NHLBI has traditionally supported our meeting and we have been honored to invite selected members of NHLBI administration as attendees. Fifth, we share the NHLBI's priority on prevention; indeed key aspects of primary and secondary prevention of cardiovascular disease that are currently in widespread routine clinical use (e.g. statin drugs) were first reported at our past meetings. Sixth, the co-Chairs have placed the highest priority on participation by individuals early in their training and early in their career development.